CKPT (Checkpoint Therapeutics Inc) Earnings per share growth rate in current year
The success of Checkpoint Therapeutics (CKPT) is based on antibody test results and FDA approval. The EPS growth trend compared to last year correlates with these expectations, with the current mark equal to 80.70. An environmental vector shifts the focus toward digital research to reduce emissions, while a neutral geopolitical status guarantees stable business operations regardless of global conflicts.
Financial and market metric breakdowns for Checkpoint Therapeutics (CKPT)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio checkpointtx.com|CKPT - Company Debts|Debts to Book Capitalization Checkpoint Therapeutics Inc|CKPT - Company Long-Term Debt|Current Liabilities Checkpoint Therapeutics|Immediate Liquidity checkpointtx.com
- net income and valuation ratios data:
CKPT - Net Profit|Company Profit Forecast Checkpoint Therapeutics|CKPT - Price to Earnings Ratio|Price to Future Earnings Ratio Checkpoint Therapeutics Inc|CKPT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Checkpoint Therapeutics Inc|CKPT - Operating profit before deduction of amortization|Earnings per share for the trailing year Checkpoint Therapeutics|CKPT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months checkpointtx.com|CKPT - Earnings growth in current year|Expected earnings per share trend next year Checkpoint Therapeutics
Basic company analysis:Checkpoint Therapeutics
Checkpoint Therapeutics is implementing robotic screening and software data automation, which directly impacts operating expenses and bottom-line net income. The EPS trend reflects the percentage change in earnings per share, comparing current calculations with last year's figures to assess the efficiency of capital expenditures. Analyzing the annual EPS range allows for the real-time tracking of yield growth rates, bypassing the delays associated with quarterly reporting.
Main competitors
BeiGene Ltd. - Earnings per share increase in current year|HALO (Halozyme Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Revolution Medicines Corp RVMD|Earnings growth in current year AAPG|Net earnings per share growth this year cgoncology.com CGON|Earnings growth in current year URGN (UroGen Pharma)|Earnings per share increase in current year BCAX|Personalis Corp - Earnings growth in current year|Earnings per share growth rate in current year Erasca Oncology|DCTH: Earnings growth in current year|Net earnings per share growth this year ymabs.com|Earnings per share growth in current year Aura Biosciences|Earnings growth in current year Candel|Earnings per share growth in current year Accuray Inc. (ARAY)|SLS: Earnings per share trend in current year|Earnings per share growth in current year Actuate Therapeutics, Inc. ACTU|citiusonc.com (CTOR) - Earnings per share growth rate in current year|TuHURA - Earnings growth in current year|Expected net earnings per share growth this year Protara Therapeutics Inc TARA|Fate Therapeutics Corp (FATE) - Earnings per share growth in current year|Earnings per share growth this year WHWK|Net earnings per share growth this year TCRX|CSBR (Champions Oncology Corp) - Net earnings per one share growth for the current year|Net earnings per share growth this year XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Earnings per share increase in current year|OS Therapies Inc - Net earnings per share growth this year|Net earnings per one share growth for the current year RADX (radiopharmtheranostics.com)|Artiva - Earnings growth in current year|Earnings per share increase in current year ANL (Adlai Nortye Ltd.)|VERU: Earnings growth in current year|Earnings per share growth rate in current year Tempest Therapeutics Inc (TPST)|Earnings per share growth in current year Xilio Therapeutics Inc|RENB: Earnings per share increase in current year|Earnings growth in current year MURA|Earnings growth in current year kairospharma.com (KAPA)|Earnings per share growth in current year OnKure Therapeutics OKUR|GDTC (CytoMed Therapeutics Ltd) - Earnings per share trend in current year|Curis Corp - Earnings growth in current year|Earnings per share growth rate in current year Apollomics, Inc.|THAR (Tharimmune, Inc.) - Net earnings per share growth this year|Advanced Biomed (ADVB) - Earnings growth in current year|Net earnings per share growth this year GNPX|CLDI (Calidi Bio) - Net earnings per one share growth for the current year|Earnings growth in current year SBFM|Expected net earnings per share growth this year xeneticbio.com|Earnings growth in current year SLRX (Salarius Pharmaceuticals)|PPBT - Net earnings per share growth this year|AONC - Earnings per share growth in current year|Expected net earnings per share growth this year BeiGene Ltd. BGNE|ELEV: Earnings growth in current year|Net earnings per share growth this year iCAD|Earnings per share growth in current year Ikena Oncology Inc.|Earnings growth in current year notablelabs.com|Earnings per share growth in current year Viracta Therapeutics (VIRX)|MOR: Earnings per share trend in current year|NAYA Bio - Net earnings per share growth this year|Net earnings per one share growth for the current year AAPGV (Ascentage)
